MZT Matritech,

The city of San Francisco and its fire department (SFFD) are responding to the alarm that firefighters have an increased risk for bladder cancer and death from the disease by providing free bladder cancer screening to all its current and retired firefighters. The NMP22� BladderChek� Test, a point-of-care urine test, developed and marketed by Matritech (Amex: MZT) is being used in the screening program. San Francisco is the first major city to fund and provide free annual testing for bladder cancer to its firefighters. To date, over 900 firefighters have been tested with the NMP22 BladderChek Test and more than 1,000 have completed voluntary cancer screening questionnaires. The San Francisco Firefighters Cancer Prevention Foundation released information today about the bladder cancer screening program at a press conference at the San Francisco city hall. About three hundred firefighters were in attendance. Mayor Gavin Newsome stood with the firefighters and spoke of his commitment and the efforts of his administration to provide the funding for the bladder cancer screening program and the NMP22 BladderChek Tests. The SFFD will be offering screening for bladder cancer annually. Stephen D. Chubb, Matritech�s Chairman and CEO said, �This action by the city of San Francisco and the San Francisco Fire Department to safeguard the health and welfare of its members is exemplary.� Mr. Chubb added, �The city, the San Francisco Firefighters Cancer Prevention Foundation, and firefighters Local 798 recognize that the key to saving lives from cancer is early detection. Education and routine testing will achieve this objective. We�re pleased that the BladderChek Test is part of this program.� The Foundation is launching a campaign urging firefighters to be aware of their potential risks for cancer and reminding them that screening may save lives. Efforts to get the city to fund and start the screening program were spearheaded by Tony Stefani, a cancer survivor who is a retired captain in the San Francisco Fire Department, and Dr. Marshall Stoller, professor and Vice Chairman, Department of Urology, University of California, San Francisco (UCSF) School of Medicine and urologist at the UCSF Medical Center. Captain (Ret.) Stefani is the founder and Chairman of the Board of the San Francisco Firefighters Cancer Prevention Foundation. Captain (Ret.) Stefani said, �It�s a voluntary program right now, but we have had about 1,000 people lining up to take the NMP22 BladderChek Test. We�ve had more than our share of guys diagnosed with bladder cancer. Hopefully, screening is going to save some lives.� Studies have shown that people who have environmental and occupational exposure to certain chemicals, burning material, and soot have a higher risk for the cancer. Prolonged exposure to benzene compounds found in burning debris is associated with bladder cancer risk. Even though firefighters wear an air pack, once the fire is knocked down, and they take their packs off, they are exposed to the smoldering material. Dr. Stoller commented, �We began screening for bladder cancer because it was apparent that there were a number of our local firefighters diagnosed with the disease. Firefighters may be at a higher risk for bladder cancer than most people. And this was appearing to be the case in San Francisco. It seemed that we might be able to do something about it, by detecting the cancer early and evaluating the incidence and risk for the cancer in this group of people.� He added, �The combination of a dipstick test to check for microscopic blood and the NMP22 test fits our needs for this screening program. They are easy tests to administer, have proven sensitivity, and are relatively inexpensive. The results are available on the spot. Our long term goal is to evaluate how many of our firefighters are getting cancer and what types of cancer. In the meantime, perhaps we are already saving lives by screening for bladder cancer.� Voluntary screening of firefighters with the NMP22 BladderChek Test is also ongoing and has occurred in a number of smaller communities throughout the country. Legislation providing annual screening for firefighters is being considered in Rhode Island, Florida, New York, and Massachusetts. Matritech�s NMP22 BladderChek Test is also being used in local wellness and occupational health programs that are testing people at risk for bladder cancer. Testing has occurred in Colorado, Wisconsin, Texas, Michigan, Kentucky, New York, Massachusetts, Washington, DC and Rhode Island. An analysis supporting the screening of high-risk groups for bladder cancer with the NMP22 BladderChek Test was reported in American Cancer Society�s journal Cancer (9/1/06) � screening for bladder cancer in high risk individuals with the NMP22 BladderChek Test could save lives and reduce overall medical expenses. All other cancer screening programs save lives but increase expenses. In a related article on screening for bladder cancer (10/06), Edward Messing, M.D., Chairman of the Urology Department, University of Rochester Medical Center reported that his 14 year follow-up study demonstrated that screening reduced bladder cancer mortality. Overall mortality was significantly lower in screened patients (43%) compared to those whose were not screened (74%). The tumors found by screening were diagnosed at earlier stages, improving outcomes and thus decreasing the number of bladder cancer deaths over time. About the NMP22� BladderChek� Test The NMP22� BladderChek� Test was developed and commercialized by Matritech, a leading developer and marketer of protein-based diagnostic products for the early detection of cancer. The NMP22 BladderChek Test detects elevated levels of the NMP22 protein marker in a single urine sample. Most healthy individuals have very small amounts of the NMP22 protein marker in their urine, but bladder cancer patients commonly have elevated NMP22 marker levels, even at early stages of the disease. The NMP22� BladderChek� Test, a painless and noninvasive assay, is the only in-office test approved by the FDA for both the diagnosis and monitoring of bladder cancer. It is used in a physician�s office, requires only four drops of urine and results are available in 30 minutes � during the patient visit, allowing a rapid and accurate way to aid in the detection of bladder cancer. The NMP22 BladderChek Test is reimbursed by Medicare and many medical insurers and has an average cost of less than $30. It also has been shown to detect over three times as many cancers as the commonly used laboratory based urine cytology test. Two studies published in the Journal of the American Medical Association (JAMA) in February 2005 and January 2006 reported on clinical data showing the NMP22 BladderChek Test used in combination with cystoscopy for the diagnosis and monitoring of bladder cancer detected up to 99% of bladder malignancies. The NMP22 BladderChek Test also detected cancers that were missed during an initial cystoscopic examination, most of which were high grade. In other clinical study analyses it was shown to detect 100% of the aggressive tumors, one of which was muscle invasive, in women with symptoms or risk factors for bladder cancer. It was also reported to detect all the transitional cell cancers that occurred in the upper urinary tract of patients with risk factors or symptoms of bladder cancer. Cystoscopy did not identify these tumors because they were outside the viewing area of the instrument. About Matritech Matritech, a leading marketer and developer of protein-based diagnostic products for the early detection of cancer, is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company�s first two products, the NMP22� Test Kit and NMP22� BladderChek� Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22� BladderChek� Test is based on Matritech�s proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech�s patent portfolio has grown to 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22� Test Kit and NMP22� BladderChek� Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company�s goal is to utilize protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com. Statement under the Private Securities Litigation Reform Act Any forward-looking statements relate to the Company's current expectations of the Company�s NMP22� products and technology. Actual results may differ materially from those predicted in such forward-looking statements due to the risks and uncertainties inherent in the Company�s business, including without limitation risks and uncertainties including those detailed in the Company's periodic reports and registration statements as filed with the Securities and Exchange Commission. These forward-looking statements are neither promises nor guarantees. There can be no assurance that the Company's expectations for its products will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Matritech undertakes no responsibility to revise or update any such forward-looking information.